Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 07, 2016 8:29 AM ET


Company Overview of Philogen S.p.A.

Company Overview

Philogen S.p.A. is a biopharmaceutical company that targets cancer and other angiogenesis-associated diseases. It engages in developing immunocytokines, antibodies, and vascular targeting drugs; the discovery, GMP production, and clinical development of immunomodulatory biopharmaceuticals; developing antibody-based therapeutics specific for markers of angiogenesis; and developing DNA-encoded chemical libraries, small molecule drug conjugates, and antibody drug conjugates. It develops DARLEUKIN (L19-IL2), an immunostimulatory compound; TELEUKIN (F16-IL2), a human immunostimulatory antibody; FIBROMUN (L19-TNF), an anti-EDB human antibody; RADRETUMAB (L19-131I), a human vascular targeting antib...

Via Bellaria, 35

Sovicille, SI 53018


Founded in 1996


39 057 717816


39 0577 1781 680

Key Executives for Philogen S.p.A.

Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Director of IP & Licensing and Director
Co-Founder, President of the Scientific Advisory Board and Director
Age: 52
Vice President and Director
Compensation as of Fiscal Year 2015.

Philogen S.p.A. Key Developments

Pfizer Exercises Options Under Antibodies Agreement with Philogen

Philogen SpA announced that Pfizer Inc. had exercised options granting exclusive rights on the development of certain antibody drug conjugates (ADCs) under an agreement signed in December 2014. Pfizer will also oversee the research and development of candidate molecules, as well as their potential marketing. In December 2014 Philogen and Pfizer signed a licence and option agreement to develop novel ADC technology based on Philogen validated antibodies.

Philogen S.p.A. Announces Commencement of Phase III Pivotal Trial in Melanoma

Philogen S.p.A. announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach. Stage IIIB/C melanoma patients are at high-risk of progression to the aggressive Stage IV of the disease, which is in most cases fatal. Surgery is the first therapeutic option in Stage IIIB/C patients, and is performed with a curative intent. However, unfortunately, most patients undergo further recurrences of disease and surgery becomes no longer feasible. Therefore the ability to eradicate metastatic lesions, using a biotherapeutic approach which provides a protective anti-cancer immunity, would offer an opportunity to prevent progression and prolong survival. In a recently published Phase II clinical trial, the Philogen group and collaborating Clinical Centers have demonstrated that the intratumoral injection of a combination of two immunocytokines (L19-IL2 and L19-TNF) is able to substantially reduce or eradicate injected melanoma lesions, with durable responses and excellent cosmetic results. In addition, there was evidence of systemic bystander effects on non-injected lesions, indicating the onset of a protective anti-cancer immunity. These data reinforce the findings of a previous Phase II clinical trial and of extensive preclinical investigations.

Boehringer Ingelheim, Philogen to Co-Develop Myeloid Leukaemia Treatments

Boehringer Ingelheim announced that it will collaborate with Philogen on the development of novel treatments for acute myeloid leukaemia. No financial terms were disclosed. Under their cooperation agreement, the companies will test "novel immunotherapy concepts" in one trial.

Similar Private Companies By Industry

Company Name Region
Omniabios S.R.L. Europe
Target Heart Biotec Srl Europe
TETHYS S.r.l. Europe
Tecnogen S.p.A. Europe
Anabasis Srl Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Philogen S.p.A., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at